Insiders · AARD

AARD insider transactions

Aardvark Therapeutics Inc. (AARD) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for AARD

• 73d
  SEC Form 4 filed by Chief Financial Officer Sun Nelson

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 73d
  SEC Form 4 filed by Chief Executive Officer Lee Tien-Li

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 73d
  SEC Form 4 filed by Chief Medical Officer Jaiman Manasi

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 134d
  Chief Executive Officer Lee Tien-Li bought $101,395 worth of shares (7,000 units at $14.48), increasing direct ownership by 0.45% to 1,551,613 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 134d
  Chief Financial Officer Sun Nelson bought $43,200 worth of shares (3,000 units at $14.40), increasing direct ownership by 3% to 108,484 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 191d
  Chief Executive Officer Lee Tien-Li exercised 1,229 shares at a strike of $4.24, increasing direct ownership by 0.08% to 1,544,613 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 191d
  Chief Operating Officer Jones Bryan exercised 1,250 shares at a strike of $4.24 (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 222d
  Chief Executive Officer Lee Tien-Li bought $96,624 worth of shares (10,000 units at $9.66), increasing direct ownership by 0.65% to 1,543,384 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 225d
  Chief Executive Officer Lee Tien-Li bought $160,654 worth of shares (20,000 units at $8.03), increasing direct ownership by 1% to 1,533,384 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 227d
  Chief Financial Officer Sun Nelson bought $48,440 worth of shares (6,000 units at $8.07), increasing direct ownership by 6% to 105,484 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 239d
  Chief Executive Officer Lee Tien-Li exercised 17,209 shares at a strike of $4.24, increasing direct ownership by 1% to 1,513,384 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Director Chi Jeffrey

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Chief Executive Officer Lee Tien-Li

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Chief Financial Officer Sun Nelson

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Director Tong Victor Edward Jr

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Chief Medical Officer Jaiman Manasi

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Director Baynes Roy D.

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Chief Operating Officer Jones Bryan

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 316d
  SEC Form 4 filed by Director Graf Susan E

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 430d
  Large owner Decheng Capital Global Life Sciences Fund Iv, L.P. converted options into 2,667,299 shares and bought $20,000,000 worth of shares (1,250,000 units at $16.00) (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 430d
  Director Chi Jeffrey converted options into 133,364 shares (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 430d
  Large owner Vickers Venture Fund Vi Pte Ltd converted options into 2,050,902 shares (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 430d
  Chief Executive Officer Lee Tien-Li converted options into 41,303 shares and bought $264,672 worth of shares (16,542 units at $16.00), increasing direct ownership by 4% to 1,496,175 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 430d
  Chief Financial Officer Sun Nelson converted options into 7,001 shares and bought $160,000 worth of shares (10,000 units at $16.00), increasing direct ownership by 21% to 99,484 units (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
• 430d
  Former 10% Owner Cormorant Asset Management, Lp converted options into 800,189 shares and bought $3,000,000 worth of shares (187,500 units at $16.00) (SEC Form 4)

  4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)